drugset
drugset / Trial / NCT06672068

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

NCT06672068 ↗

Phase 2 Not yet recruiting 60 enrolled TYK Medicines, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was a parallel, randomized, multicenter phase II clinical trial to evaluate the efficacy and safety of TY-9591 combined with platinum-based chemotherapy as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR sensitive mutations.

Timeline

Start
2025-02-20
Primary completion
2027-12-01
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TY-9591 Unknown 80 mg —
Subject TY-9591 Unknown 160 mg —
Background Carboplatin Small molecule 5 unknown —
Background Cisplatin Other / unclassified 75 mg/m2 —
Background Pemetrexed Small molecule 500 mg/m2 —

Indications

non-small cell lung carcinoma